# Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01865474` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01865474](<https://clinicaltrials.gov/study/NCT01865474>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01865474

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

## Technical summary

Registry record NCT01865474. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT01865474, source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01865474, source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)
- Primary completion: 2016-06 (actual) (ClinicalTrials.gov record NCT01865474, source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT01865474, source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)
- Countries: Indonesia (ClinicalTrials.gov record NCT01865474, source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01865474-2016-08-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): DLBS1033
- Intervention (Drug): placebo tablet of DLBS1033
- Lead sponsor: Dexa Medica Group
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Dexa Medica Group (`cardio:org-dexa-medica-group`)

## Provenance

Content hash: d1df4d43ecffa120189fa1b4d7f3fcd995a31c71dfc7cd4cbe409d2a1c17560f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
